Malaysia Pneumonia Treatment Drugs Market to be Dominated by Branded Pneumonia Treatment Drugs Pharmacies through 2028
A surge in hospital-acquired pneumonia subjects is
expected to drive the growth of the Malaysia pneumonia treatment drugs market
in the forecast period.
According
to TechSci Research report, “Malaysia Pneumonia
Treatment Drugs Market –By Region, Competition, Opportunities, and Forecast, 2028”, the Malaysia pneumonia treatment drugs market is anticipated to grow at a striking
rate in the forecast period, 2024-2028. This can be ascribed to the
growing demand for antibiotics. Antibiotics are one of the most common
treatments for pneumonia. They are used to fight the bacterial infections that
cause the disease. With the increasing number of pneumonia cases in Malaysia,
the demand for antibiotics is expected to rise. Next, there is increasing
adoption of combination therapies. Combination therapies, which use a
combination of different drugs to treat pneumonia, are becoming increasingly
popular in Malaysia. These therapies are often more effective than single drug
therapies and can also help to reduce the risk of antibiotic resistance. As a
result, healthcare providers are increasingly adopting combination therapies as
a first-line treatment for pneumonia. Moreover, the trend of telemedicine is on
a rise in Malaysia. The COVID-19 pandemic has accelerated the adoption of
telemedicine in Malaysia. Telemedicine allows patients to consult with
healthcare providers remotely, which can be especially helpful for patients
with pneumonia who may be unable to leave their homes. This trend is expected
to continue even after the pandemic, as healthcare providers look for ways to
improve access to care and reduce healthcare costs.
The pneumonia
treatment drugs market in Malaysia has seen a notable growth over the last few
years, but it is not without its challenges. One of the biggest challenges
facing the market is the increasing prevalence of antibiotic-resistant strains
of bacteria. Antibiotic resistance occurs when bacteria evolve to become
resistant to the drugs used to treat them, making it harder to treat
infections. This makes it increasingly difficult to treat pneumonia, which is
often caused by bacterial infections. The overuse and misuse of antibiotics in
Malaysia is contributing to this growing problem. Another challenge facing the
market is the lack of access to affordable drugs. Many people in Malaysia find
it difficult to afford the inflated cost of pneumonia treatment drugs. This is
particularly problematic for those living in rural areas, where access to
healthcare is limited. The Malaysian government has been taking steps to
address this issue by implementing various policies aimed at increasing access
to affordable drugs. The market is also facing challenges due to the increasing
competition from alternative treatments. Many people in Malaysia are turning to
traditional medicines and alternative therapies to treat pneumonia, instead of
relying on pharmaceutical drugs. This is partly due to the excessive cost of
drugs and the perception that traditional medicines are safer and more
effective. The Malaysian government has been working to regulate the use of
traditional medicines and promote evidence-based treatments for pneumonia.
Browse over XX
market data Figures spread through XX Pages and an in-depth
TOC on "Malaysia Pneumonia Treatment Drugs Market.”
Malaysia pneumonia treatment drugs market can be segmented by drugs, drug
class, distribution channel, and region.
Based on drug
class, the Malaysia pneumonia treatment drugs market can be segmented into antibacterial drugs, antiviral drugs,
antifungal drugs, and others. The Antibacterial drugs segment is
expected to dominate the market during the forecast period because antibiotics
are the first-line treatment for bacterial pneumonia, as they can kill the
bacteria causing the infection and prevent it from spreading. The use of
antibiotics is also highly recommended by healthcare professionals.
Based on distribution
channel, the Malaysia pneumonia treatment drugs market can be further divided into
hospital pharmacies, retail pharmacies, and online pharmacies. The Hospital pharmacies
segment dominated the market in 2022 and is expected to maintain its dominance
throughout the forecast period. This can be attributed to the fact that availability
of specialty medications. Hospital pharmacies stock a wide range of
medications, including specialty drugs that may not be readily available at
retail or online pharmacies.
Major companies
operating in Malaysia pneumonia treatment drugs market are:
·
GlaxoSmithkline
Pharmaceutical Sdn. Bhd.
·
Pfizer (Malaysia) Sdn Bhd
·
Sanofi-Aventis (Malaysia)
Sdn. Bhd.
·
Astrazeneca Sdn. Bhd.
·
Roche (Malaysia) Sdn. Bhd.
·
Bayer Co. (Malaysia) Sdn Bhd
·
Cipla Malaysia Sdn Bhd
Download Sample Report
Customers can also request for 10% free customization on this report.
“Malaysia pneumonia
treatment drugs market is expected to register significant growth during the
forecast period on account of the increasing emphasis on personalized medicine.
Personalized medicine, which uses a patient's genetic information to tailor
treatment plans, is becoming increasingly important in the Malaysia pneumonia
treatment drugs market. By using personalized medicine, healthcare providers
can identify the most effective treatments for individual patients, reducing
the risk of adverse reactions and improving treatment outcomes.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Malaysia Pneumonia Treatment Drugs Market By Drugs (Branded and Generics), By
Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, and
Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies), By Region, Competition, Forecast, & Opportunities, 2028”, has evaluated the future growth potential of Malaysia
pneumonia treatment drugs market and provides statistics & information on
market size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Malaysia pneumonia
treatment drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com